Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 5/20 | 0.76 |
| ▸ | MEN1 | O00255 | 10/20 | 0.75 |
| ▸ | KMT2A | Q03164 | 10/20 | 0.75 |
| ▸ | MYC | P01106 | 8/20 | 0.75 |
| ▸ | MAX | P61244 | 4/20 | 0.70 |
| ▸ | MAPT | P10636 | 2/20 | 0.70 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.70 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.70 |
| ▸ | RAB9A | P51151 | 2/20 | 0.67 |
| ▸ | NPC1 | O15118 | 1/20 | 0.67 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.62 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6834810 | 0.87 | IDO1 (0.78) | IDO1MEN1KMT2AMYCMAX | |
| SCHEMBL300424 | 0.86 | IDO1 (1.00) | IDO1MEN1KMT2AMYCMAX | |
| SCHEMBL6834736 | 0.86 | IDO1 (0.76) | IDO1MEN1KMT2AMYCMAX | |
| SCHEMBL3702011 | 0.86 | IDO1 (0.76) | IDO1MEN1KMT2AMYCMAX | |
| SCHEMBL6833753 | 0.86 | IDO1 (0.76) | IDO1MEN1KMT2AMYCMAX | |
| SCHEMBL3712058 | 0.86 | MEN1 (1.00) | IDO1MEN1KMT2AMYCMAX | |
| SCHEMBL300142 | 0.84 | MEN1 (0.72) | IDO1MEN1KMT2AMYCMAX | |
| SCHEMBL16107551 | 0.84 | MYC (0.85) | IDO1MEN1KMT2AMYCMAX | |
| SCHEMBL6833919 | 0.83 | IDO1 (0.74) | IDO1MEN1KMT2AMYCMAX | |
| SCHEMBL300125 | 0.83 | IDO1 (1.00) | IDO1MEN1KMT2AMYCMAX |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6749645-B2 | RED AND BLUE DIRECT DYE; HAIR | WELLA AKTIENGESELLSCHAFT (DE) | 2004-06-15 | — | — | US | claimed |
| EP-1317242-A1 | USE OF 4-NITRO-2,1,3-BENZOXADIAZOL DERIVATIVES AS DYES IN COLOURING AGENTS FOR KERATIN FIBRES | Wella Aktiengesellschaft (DE) | 2003-06-11 | — | — | EP | claimed |
| US-20020189032-A1 | Use of 4-nitro-2,1,3,-benzoxadiazole derivatives as dyes in colouring agents for keratin fibres | HFC PRESTIGE INTERNATIONAL OPERATIONS SWITZERLAND SÀRL (CH) | 2002-12-19 | — | — | US | claimed |
| WO-2002022094-A1 | USE OF 4-NITRO-2,1,3-BENZOXADIAZOL DERIVATIVES AS DYES IN COLOURING AGENTS FOR KERATIN FIBRES | WELLA AKTIENGESELLSCHAFT (DE) | 2002-03-21 | — | — | WO | claimed |
| US-20120122896-A1 | 2,1,3-BENZOXADIAZOL DERIVATIVES FOR THE INHIBITION OF INFLUENZA A AND B VIRUS AND RESPIRATORY SYNCYTIAL VIRUS REPLICATION | PIKE PHARMA GMBH (CH) | 2012-05-17 | — | — | US | disclosed |
| EP-2427442-A1 | 2,1,3-BENZOXADIAZOL DERIVATIVES FOR THE INHIBITION OF INFLUENZA A AND B VIRUS AND RESPIRATORY SYNCYTIAL VIRUS REPLICATION | Pike Pharma GmbH (CH) | 2012-03-14 | — | — | EP | disclosed |
| WO-2010128156-A1 | 2,1,3-BENZOXADIAZOL DERIVATIVES FOR THE INHIBITION OF INFLUENZA A AND B VIRUS AND RESPIRATORY SYNCYTIAL VIRUS REPLICATION | PIKE PHARMA GMBH (CH) | 2010-11-11 | — | — | WO | disclosed |
| US-6749645-B2 | RED AND BLUE DIRECT DYE; HAIR | WELLA AKTIENGESELLSCHAFT (DE) | 2004-06-15 | — | — | US | disclosed |
| US-20020189032-A1 | Use of 4-nitro-2,1,3,-benzoxadiazole derivatives as dyes in colouring agents for keratin fibres | HFC PRESTIGE INTERNATIONAL OPERATIONS SWITZERLAND SÀRL (CH) | 2002-12-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122896-A1 | 2,1,3-BENZOXADIAZOL DERIVATIVES FOR THE INHIBITION OF INFLUENZA A AND B VIRUS AND RESPIRATORY SYNCYTIAL VIRUS REPLICATION | TENT4B, IRF3, MAVS | IDO1 196/4885MEN1 4597/4885KMT2A 1674/4885 |
| US-20020189032-A1 | Use of 4-nitro-2,1,3,-benzoxadiazole derivatives as dyes in colouring agents for keratin fibres | CBR1, CYC1, CBR3 | IDO1 1716/4885MEN1 4392/4885KMT2A 2588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.